Display options
Cite
Lorthe E, Letouzey M, Torchin H, et al. Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort. BJOG. 2021;doi: 10.1111/1471-0528.17081.
Lorthe, E., Letouzey, M., Torchin, H., Foix L'Helias, L., Gras-Le Guen, C., Benhammou, V., Boileau, P., Charlier, C., Kayem, G. (2021). Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort. BJOG : an international journal of obstetrics and gynaecology, . https://doi.org/10.1111/1471-0528.17081
Lorthe, Elsa, et al. "Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort." BJOG : an international journal of obstetrics and gynaecology vol. (2021). doi: https://doi.org/10.1111/1471-0528.17081
Lorthe E, Letouzey M, Torchin H, Foix L'Helias L, Gras-Le Guen C, Benhammou V, Boileau P, Charlier C, Kayem G. Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort. BJOG. 2021 Dec 26; doi: 10.1111/1471-0528.17081. Epub 2021 Dec 26. PMID: 34954867.
Copy Download .nbib Format: NLM
Share it on

BJOG. 2021 Dec 26; doi: 10.1111/1471-0528.17081. Epub 2021 Dec 26.

Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort.

BJOG : an international journal of obstetrics and gynaecology

Elsa Lorthe, Mathilde Letouzey, Héloïse Torchin, Laurence Foix L'Helias, Christèle Gras-Le Guen, Valérie Benhammou, Pascal Boileau, Caroline Charlier, Gilles Kayem,

Affiliations

  1. Université de Paris, Epidemiology and Statistics Research Center/CRESS, INSERM, INRA, Paris, France.
  2. Unit of Population Epidemiology, Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
  3. Department of Neonatal Paediatrics, Poissy Saint Germain Hospital, Versailles Saint Quentin en Yvelines University, Poissy, France.
  4. Department of Neonatal Paediatrics, Cochin Port Royal Hospital, APHP, Paris, France.
  5. Department of Neonatal Paediatrics, Trousseau Hospital, APHP, Sorbonne University, Paris, France.
  6. Department of Paediatrics, Paediatrics Emergency Unit and General Paediatrics, Nantes University Hospital, Hôpital Mère-Enfant, CHU de Nantes, Nantes, France.
  7. UFR des Sciences de la Santé Simone Veil, Versailles St Quentin en Yvelines University, Montigny le Bretonneux, France.
  8. Université de Paris, Hôpital Universitaire Necker-Enfants Malades, Biology of Infection Unit, Division of Infectious Diseases and Tropical Medicine, Assistance Publique-Hôpitaux de Paris, Institut Pasteur, French National Reference Centre and WHO Collaborating Centre for Listeria U1117, Inserm U1117, Paris, France.
  9. Department of Gynaecology and Obstetrics, Trousseau Hospital, APHP, Sorbonne University, Paris, France.

PMID: 34954867 DOI: 10.1111/1471-0528.17081

Abstract

OBJECTIVE: To compare different antibiotic prophylaxis administered after preterm premature rupture of membranes to determine whether any were associated with differences in obstetric and/or neonatal outcomes and/or neurodevelopmental outcomes at 2 years of corrected age.

DESIGN: Prospective, nationwide, population-based EPIPAGE-2 cohort study of preterm infants.

SETTING: France, 2011.

SAMPLE: We included 492 women with a singleton pregnancy and a diagnosis of preterm premature rupture of membranes at 24-31 weeks. Exclusion criteria were contraindication to expectant management or indication for antibiotic therapy other than preterm premature rupture of membranes. Antibiotic prophylaxis was categorised as amoxicillin (n = 345), macrolide (n = 30), third-generation cephalosporin (n = 45) or any combinations covering Streptococcus agalactiae and >90% of Escherichia coli (n = 72), initiated within 24 hours after preterm premature rupture of membranes.

METHODS: Population-averaged robust Poisson models.

MAIN OUTCOME MEASURES: Survival at discharge without severe neonatal morbidity, 2-year neurodevelopment.

RESULTS: With amoxicillin, macrolide, third-generation cephalosporin and combinations, 78.5%, 83.9%, 93.6% and 86.0% of neonates were discharged alive without severe morbidity. The administration of third-generation cephalosporin or any E. coli-targeting combinations was associated with improved survival without severe morbidity (adjusted risk ratio 1.25 [95% confidence interval 1.08-1.45] and 1.10 [95 % confidence interval 1.01-1.20], respectively) compared with amoxicillin. We evidenced no increase in neonatal sepsis related to third-generation cephalosporin-resistant pathogen.

CONCLUSION: In preterm premature rupture of membranes at 24-31 weeks, antibiotic prophylaxis based on third-generation cephalosporin may be associated with improved survival without severe neonatal morbidity when compared with amoxicillin, with no evidence of increase in neonatal sepsis related to third-generation cephalosporin-resistant pathogen.

© 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.

Keywords: amoxicillin; antenatal management; cephalosporins; latency; macrolides; neurodevelopment; obstetric intervention; perinatal outcome; prematurity; prophylactic antibiotics

References

  1. Mercer BM. Preterm premature rupture of the membranes. Obstet Gynecol. 2003;101(1):178-93. - PubMed
  2. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75-84. - PubMed
  3. Schmitz T, Sentilhes L, Lorthe E, Gallot D, Madar H, Doret-Dion M, et al. Preterm premature rupture of the membranes: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2019;236:1-6. - PubMed
  4. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. 2013;12:CD001058. - PubMed
  5. Menon R, Richardson LS. Preterm prelabor rupture of the membranes: a disease of the fetal membranes. Semin Perinatol. 2017;41(7):409-19. - PubMed
  6. Hutzal CE, Boyle EM, Kenyon SL, Nash JV, Winsor S, Taylor DJ, et al. Use of antibiotics for the treatment of preterm parturition and prevention of neonatal morbidity: a metaanalysis. Am J Obstet Gynecol. 2008;199(6):620.e1-8. - PubMed
  7. Yudin MH, van Schalkwyk J, Van Eyk N. No. 233-antibiotic therapy in preterm premature rupture of the membranes. J Obstet Gynaecol Can. 2017;39(9):e207-12. - PubMed
  8. Prelabor rupture of membranes: ACOG practice bulletin, number 217. Obstet Gynecol. 2020;135(3):e80. - PubMed
  9. Thomson AJ. Care of women presenting with suspected preterm prelabour rupture of membranes from 24+0 weeks of gestation. BJOG. 2019;126:e152-66. - PubMed
  10. Ramsey PS, Nuthalapaty FS, Lu G, Ramin S, Nuthalapaty ES, Ramin KD. Contemporary management of preterm premature rupture of membranes (PPROM): a survey of maternal-fetal medicine providers. Am J Obstet Gynecol. 2004;191(4):1497-502. - PubMed
  11. Lorthe E, Ancel P-Y, Torchin H, Kaminski M, Langer B, Subtil D, et al. Impact of latency duration on the prognosis of preterm infants after preterm premature rupture of membranes at 24 to 32 weeks’ gestation: a national population-based cohort study. J Pediatr. 2017;182:47-52.e2. - PubMed
  12. Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA. 1997;278(12):989-95. - PubMed
  13. Kenyon S, Taylor D, Tarnow-Mordi W. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. Lancet. 2001;357(9261):979-88. - PubMed
  14. Sweeney EL, Dando SJ, Kallapur SG, Knox CL. The human ureaplasma species as causative agents of chorioamnionitis. Clin Microbiol Rev. 2017;30(1):349-79. - PubMed
  15. Kayem G, Doloy A, Schmitz T, Chitrit Y, Bouhanna P, Carbonne B, et al. Antibiotics for amniotic-fluid colonization by ureaplasma and/or Mycoplasma spp. to prevent preterm birth: a randomized trial. PLoS One. 2018;13(11):e0206290. - PubMed
  16. Woerther P-L, Lepeule R, Burdet C, Decousser J-W, Ruppé É, Barbier F. Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation resistance? Int J Antimicrob Agents. 2018;52(6):762-70. - PubMed
  17. Lorthe E, Benhammou V, Marchand-Martin L, Pierrat V, Lebeaux C, Durox M, et al. Cohort profile: the Etude Epidémiologique sur les Petits Ages Gestationnels-2 (EPIPAGE-2) preterm birth cohort. Int J Epidemiol. 2021;50:1428-9. - PubMed
  18. Pierrat V, Marchand-Martin L, Arnaud C, Kaminski M, Resche-Rigon M, Lebeaux C, et al. Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks’ gestation in France in 2011: the EPIPAGE-2 cohort study. BMJ. 2017;358:j3448. - PubMed
  19. Ancel P, Goffinet F, the EPIPAGE-2 Writing Group. Survival and morbidity of preterm children born at 22 through 34 weeks’ gestation in France in 2011: results of the epipage-2 cohort study. JAMA Pediatr. 2015;169(3):230-8. - PubMed
  20. Villar J, Papageorghiou AT, Knight HE, Gravett MG, Iams J, Waller SA, et al. The preterm birth syndrome: a prototype phenotypic classification. Am J Obstet Gynecol. 2012;206(2):119-23. - PubMed
  21. Maisonneuve E, Lorthe E, Torchin H, Delorme P, Devisme L, L’Hélias LF, et al. Association of chorioamnionitis with cerebral palsy at two years after spontaneous very preterm birth: the EPIPAGE-2 cohort study. J Pediatr. 2020;222:71-8.e6. - PubMed
  22. Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol. 2000;42(12):816-24. - PubMed
  23. Webbe JWH, Duffy JMN, Afonso E, Al-Muzaffar I, Brunton G, Greenough A, et al. Core outcomes in neonatology: development of a core outcome set for neonatal research. Arch Dis Child Fetal Neonatal Ed. 2020;105(4):425-31. - PubMed
  24. Ego A, Prunet C, Lebreton E, Blondel B, Kaminski M, Goffinet F, et al. Customized and non-customized French intrauterine growth curves. I - Methodology. J Gynecol Obstet Biol Reprod (Paris). 2016;45(2):155-64. - PubMed
  25. McNutt L-A, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157(10):940-3. - PubMed
  26. Chen W, Qian L, Shi J, Franklin M. Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification. BMC Med Res Methodol. 2018;18:63. - PubMed
  27. Chatzakis C, Papatheodorou S, Sarafidis K, Dinas K, Makrydimas G, Sotiriadis A. Effect on perinatal outcome of prophylactic antibiotics in preterm prelabor rupture of membranes: network meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2020;55(1):20-31. - PubMed
  28. Lee J, Romero R, Kim SM, Chaemsaithong P, Park C-W, Park JS, et al. A new antimicrobial combination prolongs the latency period, reduces acute histologic chorioamnionitis and funisitis, and improves neonatal outcomes in preterm PROM. J Matern Fetal Neonatal Med. 2016;29(5):707-20. - PubMed
  29. Ehsanipoor RM, Chung JH, Clock CA, McNulty JA, Wing DA. A retrospective review of ampicillin-sulbactam and amoxicillin + clavulanate vs cefazolin/cephalexin and erythromycin in the setting of preterm premature rupture of membranes: maternal and neonatal outcomes. Am J Obstet Gynecol. 2008;198(5):e54-6. - PubMed
  30. Wolf MF, Sgayer I, Miron D, Krencel A, Sheffer VF, Idriss SS, et al. A novel extended prophylactic antibiotic regimen in preterm pre-labor rupture of membranes: a randomized trial. Int J Infect Dis. 2020;96:254-9. - PubMed
  31. Streiner DL. Best (but oft-forgotten) practices: the multiple problems of multiplicity-whether and how to correct for many statistical tests. Am J Clin Nutr. 2015;102(4):721-8. - PubMed
  32. Woerther P-L, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev. 2013;26(4):744-58. - PubMed
  33. Committee opinion no. 712: intrapartum management of intraamniotic infection. Obstet Gynecol. 2017;130(2):e95-101. - PubMed
  34. European Committee on Antimicrobial Susceptibility Testing Data from the EUCAST MIC distribution website [cited 2021 Jul 01]. Available from: http://www.eucast.org - PubMed
  35. Viel-Theriault I, Fell DB, Grynspan D, Redpath S, Thampi N. The transplacental passage of commonly used intrapartum antibiotics and its impact on the newborn management: a narrative review. Early Hum Dev. 2019;135:6-10. - PubMed
  36. Doret Dion M, Cazanave C, Charlier C. Choix et durée de l’antibioprophylaxie en cas de rupture prématurée des membranes avant terme. RPC rupture prématurée des membranes avant terme CNGOF. Gynécol Obstét Fertil Sénol. 2018;46(12):1043-53. - PubMed
  37. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet. 2008;372(9646):1319-27. - PubMed
  38. Didier C, Streicher M-P, Chognot D, Campagni R, Schnebelen A, Messer J, et al. Late-onset neonatal infections: incidences and pathogens in the era of antenatal antibiotics. Eur J Pediatr. 2011;171(4):681-7. - PubMed
  39. Puopolo KM, Eichenwald EC. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years. Pediatrics. 2010;125(5):e1031-8. - PubMed
  40. Mercer BM, Carr TL, Beazley DD, Crouse DT, Sibai BM. Antibiotic use in pregnancy and drug-resistant infant sepsis. Am J Obstet Gynecol. 1999;181(4):816-21. - PubMed
  41. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, et al. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. Lancet. 2008;372(9646):1310-8. - PubMed
  42. Mueller NT, Bakacs E, Combellick J, Grigoryan Z, Dominguez-Bello MG. The infant microbiome development: mom matters. Trends Mol Med. 2015;21(2):109-17. - PubMed
  43. Azad MB, Konya T, Persaud RR, Guttman DS, Chari RS, Field CJ, et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG. 2016;123(6):983-93. - PubMed
  44. Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, et al. Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics. J Pediatr. 2015;166(3):538-44. - PubMed
  45. DiGiulio DB. Prematurity and perinatal antibiotics: a tale of two factors influencing development of the neonatal gut microbiota. J Pediatr. 2015;166(3):515-7. - PubMed
  46. Ruppé E, Burdet C, Grall N, de Lastours V, Lescure F-X, Andremont A, et al. Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage. Clin Microbiol Infect. 2018;24(1):3-5. - PubMed

Publication Types

Grant support